Filing Flows › Amphastar Pharmaceuticals (AMPH) › Guidance & outlook
Amphastar Pharmaceuticals (AMPH) guidance and outlook
Amphastar Pharmaceuticals' 10-Q filed Nov 5, 2026 makes 14 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 5, 2026
- We are currently developing a portfolio of generic abbreviated new drug applications, or ANDAs, biologics license applications, or BLAs, including biosimilar insulin product candidates, and proprietary product candidates, which are in various stages of development and target a variety of indications.
- At this time, we do not anticipate a material adverse effect on our overall business operations and sales.
- We anticipate that sales of glucagon will continue to decline in the future due to competitive dynamics.
- We also anticipate that sales of epinephrine and other products will continue to fluctuate depending on the ability of our competitors to supply market demands.
- Manufacturing expenses are expected to continue to increase as we remediate the conditions which led to the FDA warning letter at our IMS facility.
- We have made, and expect to continue to make, substantial investments in research and development to expand our product portfolio and grow our business.
- We expect that research and development expenses will increase on an annual basis due to increased clinical trials costs related to our proprietary, insulin and inhalation product candidates.
- As we undertake new and challenging research and development projects, we anticipate that the associated costs will increase significantly over the next several quarters and years.
- anticipate that sales of epinephrine and other products will continue to fluctuate depending on the ability of our competitors to supply market demands.
- We expect that research and development expenses will increase on an annual
- We expect our cash requirements to increase significantly as we sponsor clinical trials for, seek regulatory approvals of, and develop, manufacture and market our current development stage product candidates and pursue strategic acquisitions of businesses or assets.
- Our future capital expenditures include projects to upgrade, expand, and improve our manufacturing facilities in the United States and China, including a significant increase in capital expenditures over the next few years.
Amphastar Pharmaceuticals' latest quarter
Amphastar Pharmaceuticals, Q3 2026: revenue $208M (+8% year over year), operating margin 24.5%, net earnings $37.8M, operating cash flow $43.3M. The chart follows the revenue to costs, profit and cash.
Questions
What does Amphastar Pharmaceuticals expect?
We are currently developing a portfolio of generic abbreviated new drug applications, or ANDAs, biologics license applications, or BLAs, including biosimilar insulin product candidates, and proprietary product candidates, which are in various stages of development and target a variety of indications. At this time, we do not anticipate a material adverse effect on our overall business operations and sales. We anticipate that sales of glucagon will continue to decline in the future due to competitive dynamics.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.